Malta - English - Medicines Authority

genus pharmaceuticals limited linthwaite, huddersfied hd7 5qh, united kingdom - mucopolysaccharide polysulfuric, acid ester, salicylic acid - cream - mucopolysaccharide polysulfuric acid ester 0.2 % (w/w) salicylic acid 2 % (w/w) - topical products for joint and muscular pain

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - vindesine sulfate - powder for solution for injection - 5mg

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - desipramine hydrochloride (unii: 1y58do4my1) (desipramine - unii:tg537d343b) - desipramine hydrochloride 10 mg - desipramine hydrochloride tablets, usp is indicated for the treatment of depression. the use of maois intended to treat psychiatric disorders with desipramine hydrochloride or within 14 days of stopping treatment with desipramine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of desipramine hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration). starting desipramine hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration). desipramine hydrochloride is contraindicated in the acute recovery period following myocardial infarction. it should not be used in those who have shown prior hypersensitivity to the drug. cross-sensitivity between this and other dibenzazepines is a possibility.

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - amphetamine sulfate tablets usp, 5 mg and 10 mg are indicated for: - narcolepsy - attention deficit disorder with hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted. - exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - quinine sulfate capsules, usp is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14)].   limitations of use: quinine sulfate is not approved for: - treatment of severe or complicated p. falciparum malaria. - prevention of malaria. - treatment or prevention of nocturnal leg cramps [see warnings and precautions (5.1)]. quinine sulfate is contraindicated in patients with the following: - prolonged qt interval. one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline, who received quinine sulfate intravenously for p. falciparum malaria [see warnings and precautions (5.4) ]. - known hypersensitivity reactions to quinine. these include, but are not limited to, the following [see warnings and precautions (5.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - nifedipine - modified-release tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - nifedipine - modified-release tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - metformin hydrochloride - modified-release tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - fenofibrate micronised - oral tablet - 160mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - ramipril - oral capsule - 5mg